SCHEMBL3620154

SCHEMBL3620154

O=C(O)Nc1ccc(C(F)(F)F)cn1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.68
NPC1 O15118 2/20 0.68
PTGS1 P23219 2/20 0.63
GAA P10253 2/20 0.58
DEGS1 O15121 1/20 0.56
POLB P06746 1/20 0.55
XPO1 O14980 1/20 0.51
TRPV1 Q8NER1 2/20 0.51
HTT P42858 1/20 0.51
CDK5 Q00535 1/20 0.51
CDK5R1 Q15078 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
KMT2A Q03164 1/20 0.50
NPY5R Q15761 1/20 0.49
RPS6KA3 P51812 1/20 0.49
FGFR4 P22455 1/20 0.48
MAPKAPK2 P49137 1/20 0.48
HIF1A Q16665 1/20 0.48
EPAS1 Q99814 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23195088 0.86 RAB9A (0.64) RAB9ANPC1PTGS1GAADEGS1
SCHEMBL27038706 0.84 RAB9A (0.58) RAB9ANPC1PTGS1GAADEGS1
SCHEMBL9906892 0.84 RAB9A (0.61) RAB9ANPC1PTGS1GAADEGS1
SCHEMBL5036428 0.84 PTGS1 (0.66) RAB9ANPC1PTGS1GAADEGS1
SCHEMBL17894101 0.83 PTGS1 (0.74) RAB9ANPC1PTGS1GAADEGS1
SCHEMBL30643217 0.83 PTGS1 (0.74) RAB9ANPC1PTGS1GAADEGS1
SCHEMBL15540798 0.83 GAA (0.68) RAB9ANPC1PTGS1GAADEGS1
SCHEMBL17420794 0.82 DEGS1 (0.56) RAB9ANPC1PTGS1GAADEGS1
SCHEMBL12095613 0.82 CCR6 (0.66) RAB9ANPC1PTGS1GAADEGS1
SCHEMBL3928750 0.81 RAB9A (0.58) RAB9ANPC1PTGS1GAADEGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873288-B2 Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-01-16 US disclosed
EP-4281073-A1 COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER Ikena Oncology, Inc. (US) 2023-11-29 EP disclosed
WO-2022159986-A1 COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER Ikena Oncology, Inc. (US) 2022-07-28 WO disclosed
US-20210155601-A1 INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-05-27 US disclosed
US-10858338-B2 Inhibitors for soluble epoxide hydrolase (SEH) and fatty acid amide hydrolase (FAAH) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-12-08 US disclosed
US-20190077785-A1 INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-03-14 US disclosed
EP-3121177-B1 COMBINATIONS OF TRPV4 ANTAGONISTS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2018-08-01 EP disclosed
WO-2017160861-A1 INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-09-21 WO disclosed
EP-3121177-A1 COMBINATIONS OF TRPV4 ANTAGONISTS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2017-01-25 EP disclosed
EP-2721016-B1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2016-04-06 EP disclosed
US-20070208013-A1 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-06 US disclosed
EP-1765823-A1 PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS Bayer Pharmaceuticals Corporation (US) 2007-03-28 EP disclosed
WO-2005121147-A1 PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS BAYER PHARMACEUTICALS CORPORATION (US) 2005-12-22 WO disclosed
EP-0438209-B1 Uracil derivatives and pesticides containing the same as active ingredient NISSAN CHEMICAL IND LTD (JP) 1994-09-21 EP disclosed
US-5116404-A URACIL DERIVATIVES AND PESTICIDES CONTAINING THE SAME AS ACTIVE INGREDIENT NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1992-05-26 US disclosed
EP-0438209-A1 Uracil derivatives and pesticides containing the same as active ingredient NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1991-07-24 EP disclosed
EP-0033231-B1 INSECTICIDAL COMPOSITIONS CONTAINING 2,6-DIHALOBENZOYLUREA DERIVATIVES ELI LILLY AND COMPANY (US) 1984-06-13 EP disclosed
US-4338321-A FOR INCLUSION IN CATTLE OR POULTRY FEEDS ELI LILLY AND COMPANY (US) 1982-07-06 US disclosed
EP-0033231-A1 Insecticidal compositions containing 2,6-dihalobenzoylurea derivatives ELI LILLY AND COMPANY (US) 1981-08-05 EP disclosed
US-4281003-A 1-(2-6-Dihalobenzoyl)-3-(5-substituted-2-pyridinyl)urea insecticides and insecticidal method ELI LILLY AND COMPANY (US) 1981-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873288-B2 Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) FAAH, FAAH2, EPHX2 RAB9A 2406/4885NPC1 859/4885PTGS1 103/4885
US-20210155601-A1 INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) FAAH, FAAH2, EPHX2 RAB9A 2406/4885NPC1 859/4885PTGS1 103/4885
US-20070208013-A1 6-(Methoxymethyl)-5-(4-nitrophenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; antiproliferative agents; angiogenesis inhibition; anticarcinogenic agents; breast cancer; colon cancer; antitumor agents MKI67, CCNA1, CCNI RAB9A 4805/4885NPC1 4140/4885PTGS1 702/4885
US-10858338-B2 Inhibitors for soluble epoxide hydrolase (SEH) and fatty acid amide hydrolase (FAAH) FAAH, FAAH2, EPHX2 RAB9A 2406/4885NPC1 859/4885PTGS1 103/4885
US-20190077785-A1 INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) FAAH, FAAH2, EPHX2 RAB9A 2406/4885NPC1 859/4885PTGS1 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.